Literature DB >> 1711962

Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia.

D Faulds1, P Chrisp, M M Buckley.   

Abstract

Adenosine (adenine riboside), administered either as the free base or as the 5'-triphosphate (ATP) by rapid intravenous bolus, depresses atrioventricular (AV) nodal conduction, resulting in transient AV block. Adenosine is the active agent and ATP is rapidly converted to adenosine after exogenous administration. By blocking the anterograde AV nodal limb of a re-entrant circuit, adenosine 6 to 12 mg (or ATP 10 to 20 mg) converts almost all episodes of paroxysmal supraventricular tachycardia (PSVT) involving the AV node within 30 seconds of administration. This is at least equivalent in efficacy to verapamil in adults, and superior to lanatoside C in children, with a considerably more rapid onset of action. Furthermore, if a dose of adenosine is ineffective, the exceptionally short plasma half-life of the adenyl nucleosides (less than 10 sec) allows rapid upward dosage titration until PSVT is terminated. Because the induced conduction block primarily affects the AV node, adenosine is a useful diagnostic tool in patients with broad or narrow QRS complex tachycardia; it terminates arrhythmias dependent on the AV node, unmasks other supraventricular mechanisms during transient AV block, but almost always has no effect on ventricular tachycardia. Noncardiac adverse effects, i.e. flushing, dyspnoea and chest pain, may occur during acute arrhythmia termination or diagnosis with adenosine, and arrhythmias may develop; however, these effects are usually transient (lasting less than 1 minute). Adenosine has also been used to induce coronary vasodilation in patients undergoing thallium-201 single photon emission computed tomography (201Tl SPECT), 2-dimensional echocardiography or positron emission tomography to evaluate suspected coronary artery disease. Intravenous infusion of adenosine 140 micrograms/kg/min for 6 minutes was generally associated with only mild adverse effects. These usually resolved within 1 to 2 minutes of discontinuing adenosine, although occasionally patients required aminophylline and/or nitroglycerin (glyceryl trinitrate). Diagnoses based on the results of scintigraphy were of a sensitivity, specificity and predictive accuracy comparable to those achieved with exercise- or dipyridamole-201Tl SPECT. Adenosine is therefore particularly suitable for the diagnosis of tachycardias and the acute management of PSVT involving the AV node in all age groups, without the risks of cardiac arrest and hypotension associated with verapamil. Furthermore, intravenous adenosine infusion may be used to induce coronary vasodilation in patients unable to perform exercise stress tests for 201Tl scintigraphy, and is well tolerated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711962     DOI: 10.2165/00003495-199141040-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  123 in total

1.  Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle.

Authors:  J G Dobson
Journal:  Circ Res       Date:  1978-11       Impact factor: 17.367

Review 2.  Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies.

Authors:  S Viskin; B Belhassen
Journal:  Am Heart J       Date:  1990-07       Impact factor: 4.749

3.  Effect of infused adenosine on cardiac output and systemic resistance in normal subjects.

Authors:  A Bush; C M Busst; B Clarke; P J Barnes
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Death with dipyridamole-thallium imaging.

Authors:  H Z Friedman; S F Goldberg; A M Hauser; W W O'Neill
Journal:  Ann Intern Med       Date:  1988-12-15       Impact factor: 25.391

5.  Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow.

Authors:  D G Babbitt; R Virmani; H D Vildibill; E D Norton; M B Forman
Journal:  Am Heart J       Date:  1990-10       Impact factor: 4.749

Review 6.  Understanding and treating supraventricular arrhythmias.

Authors:  J L Bauman
Journal:  Clin Pharm       Date:  1983 Jul-Aug

7.  Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias.

Authors:  J P diMarco; T D Sellers; B B Lerman; M L Greenberg; R M Berne; L Belardinelli
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

8.  Differential electrophysiologic properties of decremental retrograde pathways in long RP' tachycardia.

Authors:  B B Lerman; M Greenberg; E D Overholt; C D Swerdlow; R T Smith; T D Sellers; J P DiMarco
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

9.  Value and limitations of intracoronary adenosine for the assessment of coronary flow reserve.

Authors:  F Zijlstra; Y Juillière; P W Serruys; J R Roelandt
Journal:  Cathet Cardiovasc Diagn       Date:  1988

10.  Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.

Authors:  M J Griffith; N J Linker; C J Garratt; D E Ward; A J Camm
Journal:  Lancet       Date:  1990-09-15       Impact factor: 79.321

View more
  15 in total

1.  Effects of dose ranging of adenosine infusion on electrocardiographic findings during and after general anesthesia.

Authors:  Yan-Xia Sun; Ashraf S Habib; Tom Wenger; Irwin Gratz; David Glick; Rishimani Adsumelli; Mary R Creed; Tong J Gan
Journal:  J Anesth       Date:  2012-06-03       Impact factor: 2.078

2.  Adenosine and cardiac arrhythmias.

Authors:  C J Garratt; A D Malcolm; A J Camm
Journal:  BMJ       Date:  1992-07-04

Review 3.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 4.  Cardiac arrhythmias in childhood. Diagnostic considerations and treatment.

Authors:  J F Strasburger
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Pharmacokinetics of exogenous adenosine in man after infusion.

Authors:  P Blardi; F Laghi Pasini; R Urso; C Frigerio; L Volpi; L De Giorgi; T Di Perri
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  A case of life-threatening supraventricular tachycardia storm associated with theophylline toxicity.

Authors:  Keishi Ichikawa; Tadashi Wada; Takahiro Nishihara; Masahiro Tsuji; Atsushi Mori; Fumi Yokohama; Daiji Hasegawa; Kenji Kawamoto; Machiko Tanakaya; Yusuke Katyama; Satoru Sakuragi; Hiroshi Ito
Journal:  J Cardiol Cases       Date:  2017-03-06

Review 7.  The therapeutic and diagnostic cardiac electrophysiological uses of adenosine.

Authors:  A D Malcolm; C J Garratt; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

8.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

9.  Adenosine-tri-phosphate treatment for supraventricular tachycardia in infants.

Authors:  D De Wolf; G Rondia; H Verhaaren; D Matthys
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

10.  Adenosine-induced ventricular arrhythmias in patients with supraventricular tachycardias.

Authors:  Cagatay Ertan; Ilyas Atar; Oyku Gulmez; Asli Atar; Aliseydi Ozgul; Alp Aydinalp; Haldun Müderrisoğlu; Bülent Ozin
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.